share_log

Intuitive Surgical | 10-Q: Q2 2024 Earnings Report

Intuitive Surgical | 10-Q: Q2 2024 Earnings Report

直觉外科公司 | 10-Q：2024财年二季报
美股SEC公告 ·  2024/07/20 05:06

Moomoo AI 已提取核心信息

Intuitive Surgical reported strong Q2 2024 results with total revenue up 14% to $2.01 billion. Da Vinci procedures grew 17% to approximately 661,000, while Ion procedures surged 82% to 23,200. Instruments and accessories revenue increased 16% to $1.24 billion, and systems revenue rose 14% to $448 million.The company placed 341 da Vinci systems in Q2, including 70 next-generation da Vinci 5 systems, bringing the installed base to 9,203 systems globally. Gross profit margin improved to 68.3% from 66.7% last year. Operating income increased 22% to $567 million, with net income rising to $531.5 million.Looking ahead, Intuitive faces some headwinds including hospital financial pressures, staffing shortages, and increasing competition in markets like China. However, the company remains well-positioned with a strong balance sheet of $7.68 billion in cash and investments. Intuitive continues to invest heavily in R&D and manufacturing capabilities to drive long-term growth in robotic-assisted surgery and minimally invasive care.
Intuitive Surgical reported strong Q2 2024 results with total revenue up 14% to $2.01 billion. Da Vinci procedures grew 17% to approximately 661,000, while Ion procedures surged 82% to 23,200. Instruments and accessories revenue increased 16% to $1.24 billion, and systems revenue rose 14% to $448 million.The company placed 341 da Vinci systems in Q2, including 70 next-generation da Vinci 5 systems, bringing the installed base to 9,203 systems globally. Gross profit margin improved to 68.3% from 66.7% last year. Operating income increased 22% to $567 million, with net income rising to $531.5 million.Looking ahead, Intuitive faces some headwinds including hospital financial pressures, staffing shortages, and increasing competition in markets like China. However, the company remains well-positioned with a strong balance sheet of $7.68 billion in cash and investments. Intuitive continues to invest heavily in R&D and manufacturing capabilities to drive long-term growth in robotic-assisted surgery and minimally invasive care.
直觉外科公司发布了2024年第二季度强劲的业绩，总营业收入同比增长14%，达20.1亿美金。达芬奇手术增长了17%，约为661,000例，而Ion手术激增82%，达23,200例。仪器和配件的营业收入增长16%，达12.4亿美金，系统营业收入增长14%，达44800万美金。该公司在第二季度安装了341台达芬奇系统，其中包括70台下一代达芬奇5系统，使全球已安装的系统总数达到9,203台。毛利润率从去年的66.7%提升至68.3%。营业收入增长22%，达56700万美金，净利润上升至53150万美金。展望未来，直觉公司面临一些阻力，包括医院的财务压力、人员短缺以及在中国等市场竞争的加剧。然而，公司的财务状况依然良好，拥有76.8亿美金的现金和投资。直觉公司继续在研发和制造能力上进行重磅投资，以推动机器人辅助手术和微创护理的长期增长。
直觉外科公司发布了2024年第二季度强劲的业绩，总营业收入同比增长14%，达20.1亿美金。达芬奇手术增长了17%，约为661,000例，而Ion手术激增82%，达23,200例。仪器和配件的营业收入增长16%，达12.4亿美金，系统营业收入增长14%，达44800万美金。该公司在第二季度安装了341台达芬奇系统，其中包括70台下一代达芬奇5系统，使全球已安装的系统总数达到9,203台。毛利润率从去年的66.7%提升至68.3%。营业收入增长22%，达56700万美金，净利润上升至53150万美金。展望未来，直觉公司面临一些阻力，包括医院的财务压力、人员短缺以及在中国等市场竞争的加剧。然而，公司的财务状况依然良好，拥有76.8亿美金的现金和投资。直觉公司继续在研发和制造能力上进行重磅投资，以推动机器人辅助手术和微创护理的长期增长。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Pulse Biosciences
    PLSE
    -- 16.600
    Anbio Biotechnology
    NNNN
    -- 7.550
    哈佛生物科学
    HBIO
    -- 0.610
    STAAR Surgical
    STAA
    -- 17.790
    Merit Medical Systems
    MMSI
    -- 103.940
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日